| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 1995 American Heart Association, Inc.
Articles |
Relations Between Plasma Lipids and Postheparin Plasma Lipases and VLDL and LDL Subfraction Patterns in Normolipemic Men and Women
From the Department of Pathological Biochemistry, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.
Correspondence to Dr C.E. Tan, Department of Pathological Biochemistry, University of Glasgow, Glasgow Royal Infirmary, Glasgow, G4 0SF, UK.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract VLDL1, VLDL2, IDL, and LDL and its subfractions (LDL-I, LDL-II, and LDL-III) were quantified in 304 normolipemic subjects together with postheparin plasma lipase activities, waist/hip ratio, fasting insulin, and glucose. Concentrations of VLDL1 and VLDL2 rose as plasma triglycerides (TGs) increased across the normal range, but the association of plasma TGs with VLDL1 showed a steeper slope than that of VLDL2 (P<.001). Plasma TG level was the most important determinant of LDL subfraction distribution. The least dense species, LDL-I, decreased as the level of this plasma lipid rose in the population. LDL-II in both men and women exhibited a positive association with plasma TG level in the range 0.5 to 1.3 mmol/L, increasing from about 100 to 200 mg/dL. In contrast, within this TG range the LDL-III concentration was low (
30 mg/dL) and changed
little. As plasma TGs rose from 1.3 to 3.0 mmol/L there was a
significant fall in LDL-II concentration in men (r=-.45,
P<.001) but not in women (r=-.1, NS).
Conversely, above the TG threshold of 1.3 mmol/L there was a steeper
rise in LDL-III concentrations in men than in women
(P<.001); 42% of the men had an LDL-III in the range
associated with high risk of heart disease (>100 mg lipoprotein/dL
plasma) compared with only 17% of the women. Other influences on the
LDL subfraction profile were the activities of lipases and
parameters indicative of the presence of insulin
resistance. Men on average had twice the hepatic lipase activity of
women. This enzyme was not strongly associated with variation in the
LDL subfraction profile in men, but in women it was correlated with
LDL-III (r=.39, P=.001) and remained a
significant predictor in multivariate analysis.
Increased waist/hip ratio, fasting insulin, and glucose were correlated
negatively with LDL-I and positively with LDL-III, primarily, at least
in the case of LDL-III, through raising plasma TGs. On the basis of
these cross-sectional observations we postulate the following model
for the generation of LDL-III. Subjects develop elevated levels of
large TG-rich VLDL1 for a number of reasons, including
failure of insulin action. The increase in the concentration of
VLDL1 expands the plasma TG pool, and this, via the action
of cholesteryl ester transfer protein (which facilitates neutral lipid
exchange between lipoprotein particles), promotes the net transfer of
TGs into LDL-II, the major LDL species. A hepatic lipase activity in
the male range (due possibly to androgen/estrogen imbalance in women)
is then required to lipolyze TG-enriched LDL-II and to generate a
concentration of small, dense LDL-III that exceeds the risk limit of
100 mg/dL.
Key Words: VLDL subfraction • IDL • LDL subfractions • atherogenic lipoprotein phenotype • hepatic lipase
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Plasma lipoproteins are known to play a causative role in atherosclerosis and its clinical manifestation, CHD. Raised plasma cholesterol levels, particularly in the LDL fraction, correlate positively with the incidence of CHD, whereas HDL displays a negative association. The risk associated with elevations in plasma TGs, which are carried mainly in VLDL, remains controversial. However, it is increasingly clear that one way in which this plasma lipid relates to CHD is through its influence on the structure of LDL and HDL, in particular its relation to the subfraction distribution within these density classes.1 2 3 Recent advances in methods for separating and quantifying lipoprotein subclasses have improved our understanding of the role of lipoproteins in the pathophysiology of CHD. The VLDL fraction can be divided into at least two components of differing size, density, and metabolic properties.4 5 LDL is thought to consist of at least three to seven subpopulations,1 6 7 and IDL has been reported to contain larger IDL1 and smaller IDL2 particles.8 The heterogeneity observed within these density intervals may be linked since the conversion of VLDL to LDL does not occur via a single delipidation chain. Rather, parallel processing pathways operate within the delipidation cascade.9 10 For example, when delipidated, large VLDL (VLDL1, 60 to 400 Svedberg flotation units) give rise to remnants in the smaller VLDL2 (Sf 20 to 60) and IDL (Sf 12 to 20) density intervals; these are inefficiently converted to a class of LDL (Sf 0 to 12) that is cleared slowly from the plasma. Newly synthesized small VLDL (VLDL2), on the other hand, is rapidly and almost quantitatively delipidated to LDL, which is catabolized relatively rapidly.9
Metabolic studies of LDL have been complemented in recent years by examination of its subfraction distribution by the high-resolution techniques of gradient gel electrophoresis6 and density-gradient ultracentrifugation.7 Austin et al1 11 have demonstrated an association between a particular LDL phenotype and CHD risk. The atherogenic lipoprotein phenotype, defined by the predominance of small, dense LDL ("pattern B") and moderately elevated plasma TG and low HDL-C levels, is associated with a threefold increase in CHD risk.1 11 By using the density-gradient technique to quantify individual LDL species, we have translated the atherogenic lipoprotein phenotype into a plasma concentration of LDL-III (d=1.045 to 1.065 kg/L) of greater than 100 mg lipoprotein/dL plasma12 and have shown that this, when present, gives a sevenfold increased risk in a case-control study of myocardial infarct survivors versus normal subjects. The atherogenic lipoprotein phenotype is also linked to the presence of insulin resistance as an underlying metabolic disorder.13 The insulin-resistance syndrome, which is characterized by fasting hyperinsulinemia and exaggerated insulin response to a glucose challenge,14 is considered to be an independent risk factor for CHD. Furthermore, insulin-resistant individuals, especially those with frank non–insulin-dependent diabetes mellitus, have alterations in VLDL structure and metabolism, with an abundance of the larger, TG-rich VLDL species.15 Insulin resistance is associated with an increase in central obesity as indicated by increased BMI and WHR. However, the precise effects of changes in anthropometric indices on plasma lipoprotein subfraction distributions are unknown, although they have been linked to an LDL pattern dominated by small, dense LDL.16 Epidemiological studies have further shown that atherogenic lipoprotein phenotype expression is age and sex dependent.17
In our study of a large group of subjects whose plasma lipid values spanned the normal range, we sought to understand the relations between apoB-containing lipoproteins in terms of their overall concentration, composition, and subfraction distribution. These parameters were also related to total plasma lipid levels, anthropometric indices, and gender. Our principal hypothesis was that the presence of elevated plasma TGs (possibly associated with insulin resistance) and the activity of lipolytic enzymes were together responsible for the accumulation of small, dense LDL. Further, we examined the extent to which the male-female difference in CHD risk could be explained by the variation in lipoprotein subfraction profiles.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
Three hundred four healthy volunteers (140 men and 164 women) aged 18 to 69 years were recruited from various sources. These included staff at the Glasgow Royal Infirmary, responders to newspaper advertisements, and healthy family members of patients who had had a coronary bypass grafting operation. All had no history or symptoms of CHD or diabetes mellitus. There was also no known history of dyslipidemia or treatment for dyslipidemia; serum urea and electrolytes were measured to exclude those with renal impairment. The study was approved by the Research Ethics Committee of the Glasgow Royal Infirmary, and each subject gave written informed consent.
Blood samples were obtained from volunteers after a 12-hour overnight fast. Blood was collected by venipuncture with potassium-EDTA (final concentration, 1 mg/mL) as anticoagulant. Plasma was harvested at 4°C by low-speed centrifugation, and aliquots for lipid and lipoprotein measurements and LDL subfractionation were used immediately. Those for insulin assay were snap-frozen at -20°C and analyzed in batches at a later time. Of the 304 volunteers, 137 underwent measurement of fasting postheparin plasma lipases. Ten minutes after the administration of 70 U heparin/kg body wt IV, 10 mL blood was collected into lithium-heparin tubes on ice. Plasma obtained from these samples was frozen immediately and stored at -70°C prior to analysis. In 191 volunteers height, weight, blood pressure, waist, and hip measurements were taken. BMI was calculated as the weight (in kilograms) divided by the height (in meters) squared, and the WHR was also determined. Waist was defined as the smallest circumference between the rib cage and iliac crest and hip as the largest circumference between waist and thigh taken in the standing position.18 Blood pressure was the average of two readings taken in the sitting position from the right arm after a 15-minute rest. Korotkov phase V was taken as the diastolic pressure.
Plasma Lipids, Lipoproteins, and Lipoprotein
Fractionation
Plasma cholesterol, TG, HDL-C, VLDL-C, and LDL-C
measurements were performed by a modification of the standard Lipid
Research Clinics protocol.19 Total LDL was isolated by
preparative ultracentrifugation at
d=1.019 to 1.063 kg/L in a fixed-angle rotor (50.4 Ti;
Beckman Industries Inc). VLDL1 (Sf 60 to 400),
VLDL2 (Sf 20 to 60), IDL (Sf
12 to 20), and LDL (Sf 0 to 12) were prepared from plasma
by a modification of the cumulative-gradient
centrifugation technique described by Lindgren et
al.20 The TG, free cholesterol, cholesteryl
ester (calculated as the total minus free cholesterol
content multiplied by 1.68 to account for the mass of the fatty acid),
phospholipid, and protein contents of the lipoproteins were
assayed,21 and lipoprotein concentrations were calculated
as the sum of these components (expressed as milligrams per deciliter
of plasma). Recoveries of the four apoB-containing lipoproteins based
on the sum of their cholesterol content compared with the
"non–HDL-C" measured by standard methods19 exceeded
85% in both men and women. LDL subfractions were isolated from fresh
plasma by nonequilibrium density-gradient
ultracentrifugation7 by using a
six-step, curvilinear salt gradient. Following
centrifugation for 24 hours at 40 000 rpm and 23°C
in a swinging-bucket rotor (SW40; Beckman Industries Inc), the tube
contents were eluted by upward displacement, and the presence of LDL
fractions was detected by continuous monitoring at 280 nm. Three
distinct subfractions were resolved in almost all subjects. The
subfraction areas under the concentration curve were quantified (Data
Graphics; Beckman Industries Inc), corrected for differences in
extinction coefficient, and expressed as percentage of total
LDL.7 The value for total LDL (d=1.019 to 1.063
kg/L) lipoprotein mass (free cholesterol+TG+cholesteryl
ester+ phospholipid+protein), determined as above, was then used to
generate individual subfraction concentrations in milligrams of
lipoprotein per deciliter of plasma. The lipoprotein
core-to-coat ratio was calculated as the ratio of the sum of
"core" components (mass of TGs and cholesteryl esters) to the sum
of "coat" constituents (mass of phospholipid, free
cholesterol, and protein). This provided an index of
particle size given that all lipoproteins possess a pseudomicellar
spherical structure.22 Lipoprotein(a), the density
interval of which overlaps that of LDL-III, was not found to
contaminate significantly the LDL-III fraction. When gradient fractions
were assayed by enzyme-linked immunosorbent assay (Innotest SA) in
normolipidemic subjects with a wide range of lipoprotein(a) levels, ie,
up to 150 mg/dL, less than 6% of the lipoprotein(a) was found in the
LDL-III fraction. Lipoprotein(a) eluted from the gradient after the
LDL-III peak.
Postheparin HL and LPL Assays
LPL and HL were assayed in postheparin
plasma.21 Gum arabic–stabilized TG emulsion
containing glycerol tri[1-14C]oleate at a specific
activity of 30 µCi/mmol TG fatty acid23 was used as
substrate. For the specific assay of LPL, plasma was preincubated with
sodium dodecyl sulfate to inhibit HL, and pooled preheparin
plasma was added to the incubation as a source of cofactor apoC-II to
activate the LPL enzyme. HL was assayed in the presence of 1.0
mol/L NaCl to inactivate LPL.23 Enzyme
activities are expressed in micromoles of fatty acids released per hour
per milliliter of plasma.
Insulin Assays
Plasma insulin was measured by an immunoradiometric assay with
two antibodies. The 125I-labeled monoclonal
anti-insulin antibody was prepared from mouse hybridoma cells
(Scottish Antibody Production Unit), and the solid-phase
guinea pig anti-insulin antibody was coupled to Sepharose gel
(Scottish Antibody Production Unit). Plasma samples were thawed
immediately prior to analysis. The assay had a working range of
0.5 to 50 mU/L with an intra-assay coefficient of variation of
<10% and an interassay variation of 8% to 14%. The assay showed
significant cross-reaction with intact human proinsulin (60%).
Statistical Methods
Statistical analysis and manipulations were performed by
using the personal computer version of MINITAB release 9
for Windows (Minitab Inc). All variables were assessed by drawing
normality plots by using the MINITAB routine. The
Anderson-Darling test (P<.05) for deviation from normality
was employed, and in instances in which values were not normally
distributed, appropriate transformations were performed to obtain a
normal distribution. The following factors were subjected to
loge transformation: BMI, WHR, and plasma TG, HDL-C,
fasting insulin, LPL, HL, VLDL1,
VLDL2, LDL-I, LDL-II, and LDL-III
concentrations. Plasma VLDL-C was normalized by taking the square root,
and fasting glucose was normalized by squaring it. All other
variables were examined untransformed. Associations between
variables were tested by calculating the Pearson correlation
coefficient (r) and the coefficient of determination
(r2), which was expressed as a
percentage, (ie, r2 gives the percentage
of variation in the dependent variable that is explained by
variations in the independent variable). The significance of
association between pairs of variables was determined by linear
regression. Multivariate analysis was employed
to determine the extent to which age, sex, general obesity (BMI),
central obesity (WHR), and markers of insulin resistance (fasting
glucose and insulin) explained the variability in
postheparin plasma LPL and HL activity and
VLDL1, VLDL2, IDL, LDL,
and LDL subfraction concentrations. This was conducted by using the GLM
ANOVA in MINITAB, which permitted the inclusion of
categorical variables (ie, sex), and multiple regression, which
generated an overall coefficient of determination for a given set of
variables. It should be noted that the GLM gives
r2 values that relate to the independent
contribution of variables whereas the overall
r2 determined by multiple regression is
usually higher and takes into account the potential interaction between
correlated variables. For consistency the same panel of
variables (anthropometric indices, markers of insulin resistance,
and lipases) was included as predictors in all GLM models of
lipoprotein subfraction distributions. Plasma TG level was added to the
models for IDL, LDL, and LDL subfractions to explore previously
identified relations.1 2 12 Not all tests were performed
on all subjects within the survey. For reasons of practicality, some
tests were carried out on limited numbers of subjects, eg, IDL
measurements, postheparin plasma lipase measurements, and
fasting insulin determinations. The plasma lipid levels, age, and sex
distributions of those who had IDL or lipases measured did not differ
significantly from the whole group, and thus in each statistical test
the maximum available information has been used.
Anthropometric indices and plasma lipid and lipoprotein levels were compared between men and women by using transformed data (where appropriate) and testing with Student's unpaired t tests. A Bonferroni correction was employed to allow for multiple comparisons. Comparison of slopes for the regression of VLDL1, VLDL2, or LDL-III versus plasma TGs and LDL TGs versus HL in men and women was done by using the pairwise-slopes routine in MINITAB and tested for significance with the Mann-Whitney U test. There were 18 perimenopausal and postmenopausal women, of whom four were on hormone replacement therapy; the hormonal status of the remaining 14 was unknown. The effect that menopause and hormone replacement therapy have on lipids24 25 26 and lipases is well documented, and hence, in each instance, analyses were performed with and without these 18 subjects to ensure that the menopausal state or hormone replacement therapy did not unduly influence the results. Their inclusion did not affect the overall findings. Ninety-seven of the volunteers came from 19 different families and were related. The results were initially analyzed with all related family members excluded and then again with the 97 included. The data were not skewed by the inclusion of these family members, and hence they are present in the final analyses.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Anthropometric Indices and Plasma Lipids and Lipases
Age, systolic blood pressure, BMI, hip circumference, plasma cholesterol, LDL-C, and VLDL-C were similar between the sexes (Table 1
). The men were generally heavier, but
this was in keeping with their height since there was no sex difference
in BMI. However, men had a significantly greater waist circumference
and consequently a bigger WHR. They also had higher plasma TGs, plasma
cholesterol/HDL ratio, and lower total HDL-C. The mean
postheparin HL activity was twice as high in men, but there
was no difference between men and women in LPL activity. Age, BMI, WHR,
and plasma TGs showed significant positive associations with plasma
cholesterol and LDL-C by univariate
analysis of this normolipemic group of men and women (data not
shown). Multivariate analysis revealed that
only age and plasma TGs were significant independent predictors of
LDL-C. Variation in plasma TG levels in the population correlated most
strongly with BMI, WHR, fasting insulin, and LPL, and of these age, LPL
and fasting insulin remained significant predictors in
multivariate analysis, accounting for 20% of
the variability in this lipid (data not shown). BMI, WHR, fasting
insulin, LPL, HL, and plasma TGs all showed significant relationships
with HDL-C in univariate analysis, but in a
multivariate model containing these variables only
fasting insulin, LPL, HL, and plasma TGs remained significant
predictors (fasting insulin, plasma TGs, and HL were negative; LPL was
positive), and together they accounted for 39% of its variability.
Postheparin HL activity had significant associations with
BMI, WHR, and fasting insulin in univariate
analysis (Table 2). By using the GLM, we
ascertained that sex alone accounted for 28.5% of the variability in
HL. When included in a model with age, measures of obesity, and insulin
resistance, sex was still the most significant predictor (GLM [A],
Table 2). The multivariate model (GLM [B]), in which
sex was excluded to reveal the effects of other potential factors,
indicated that age and WHR were significant predictors that together
accounted for 23% of HL variability. BMI and fasting insulin had
significant associations with LPL activity in univariate
analysis, but none were significant in the
multivariate model.
|
|
Chemical Compositions of ApoB-Containing Lipoproteins
The percentage contribution of protein to lipoprotein mass (ie,
grams per 100 g lipoprotein) increased steadily from 13.8±0.7% in
VLDL1 to 16.6±0.5% in VLDL2,
19.8±0.3% in IDL, and 24.5±0.6% in LDL for both men and women.
Relative TG content, on the other hand, decreased 10-fold, from
59.4±1.3% in VLDL1 to 38.0±1.0% in
VLDL2, 12.8±0.7% in IDL, and 4.9±0.1% in
LDL. The percentage of cholesteryl ester increased steadily across the
lipoproteins (11.8±0.7% in VLDL1, 24.4±0.9% in
VLDL2, and 32.4±0.8% in LDL), but it was
maximal in IDL (43.4±0.7%); it should be noted, however, that IDL
compositions were performed on only half the subjects. Free
cholesterol showed a similar pattern, with a
consistent increase from VLDL1 (1.3±0.2%) through
VLDL2 (2.9±0.3%) and IDL (6.0±0.3%) to LDL
(11.2±0.4%). Phospholipid content was relatively consistent
across the lipoproteins (14.7±1.5% in VLDL1,
18.9±1.2% in VLDL2, 18.1±0.5% in IDL, and
27.2±1.3% in LDL). These data are in good agreement with previous
findings.9 Significant male-female differences were
found in VLDL1 phospholipid (17.7±1.9% in men versus
11.6±1.0% in women, P<.01) and VLDL2
phospholipid (21.6±1.4% in men versus 16.2±0.8% in women,
P<.001) contents, but only VLDL2
phospholipid remained significantly different (P<.05) after
Bonferroni correction.
Regulation of VLDL Subfraction Composition and
Distribution
As plasma TG levels rose across the normal range (Fig 1), both VLDL1 and VLDL2
total lipoprotein concentrations increased (r=.81,
P<.001 and r=.57, P<.001 for plasma
TGs versus VLDL1 and VLDL2,
respectively), but the increment in VLDL1 was greater than
that of VLDL2 as tested by comparison of the
regression slopes (VLDL1=80.4 TG-37.9 versus
VLDL2=26.3 TG+13.5, P<.001). The
relationships were similar in both men and women with the ratio of
VLDL1 to VLDL2 total lipoprotein rising
from 1.0 at 0.5 mmol/L to 2.0 at 2.0 mmol/L plasma TGs.
|
In univariate analysis, measures of obesity (BMI
and WHR) as well as fasting glucose and insulin levels, LPL, and HL
were significantly associated with VLDL1 concentrations
(Table 3). Similarly, the same variables with the
exception of HL also had significant relationships with
VLDL2, but with the addition of age as a
further factor. In multivariate analysis only
HL was a significant predictor of VLDL1, while age
and LPL were the significant predictors of VLDL2
concentration (Table 3).
|
Examination of VLDL1 and VLDL2 compositions and calculation of the core-to-coat ratio in the lipoprotein particle indicated that the content and dimensions of the VLDL1 and VLDL2 particles remained relatively constant across the plasma TG range. Linear regression of core-to-coat ratios versus plasma TGs revealed the following regression equations: VLDL1 core-to-coat, 2.74-0.4 TG (r=.14, NS) and VLDL2 core-to-coat, 1.37-0.1 TG (r=.16, P<.05). This implied that the increase in VLDL TGs as well as VLDL mass was the result of increasing numbers of particles and not particle size. Likewise, the cholesterol-to-protein ratio in these VLDL subfractions was unchanged throughout the plasma TG range. Variation in the level of plasma cholesterol in this subject group was not associated with changes in the concentrations of VLDL1 and VLDL2 (data not shown).
Regulation of IDL Composition and Concentration
The plasma concentration of IDL rose as plasma
cholesterol increased across the normal range
(r=.71, P<.001), and this lipoprotein
accounted for about 16% of plasma cholesterol (IDL
cholesterol content divided by total plasma
cholesterol) (Fig 2). The association
between concentration of the lipoprotein and plasma TG levels was
weaker (r=.41, P<.001; data not shown). In
univariate analysis, age, BMI, WHR, fasting
glucose, and plasma TGs were important predictors of IDL concentration
(Table 4). However, HL and plasma TGs were the only
significant predictors in the multivariate model. The
IDL core-to-coat ratio changed little across the range of
plasma cholesterol levels seen in the present study
(r=-.2, P=.05), but the IDL
cholesterol-to-protein ratio showed a steady
increase with increasing plasma cholesterol levels
(r=.55, P<.001). Further analysis showed
that as plasma cholesterol rose, IDL became enriched in
cholesteryl esters and depleted in TGs; the cholesteryl
ester–to-TG ratio exhibited a significant positive correlation
with plasma cholesterol (r=.46,
P<.001) (Fig 2). In contrast, the cholesteryl
ester–to-TG ratio in VLDL1,
VLDL2, and LDL remained constant across the
cholesterol range. Again, these relationships were the same
in men and women.
|
|
Regulation of LDL Concentration, Composition, and Subfraction
Distribution
The total LDL concentration in both men and women showed a
significant positive relationship with plasma TG levels below 1.3
mmol/L (r=.30, P<.01) but no association above
that value (r=.17, NS). (A value of 1.3 mmol/L is used
throughout this article as the plasma TG threshold at which LDL-III
concentrations begin to rise significantly. It is the approximate
plasma TG level at which LDL-II reaches a maximum in men.) There was
also, predictably, a strong positive association between plasma
cholesterol and total LDL concentration (r=.73,
P<.001) (data not shown). Age, BMI, WHR, and fasting
insulin were significant correlates of total LDL concentration in
univariate analyses (Table 4
), but only age and
plasma TGs remained significant predictors in
multivariate analysis. There was little
variation in LDL composition as plasma lipid levels changed. The
cholesterol-to-protein ratio (0.81±0.01) and the
core-to-coat ratio (0.46±0.01) remained constant across the
plasma cholesterol range in contrast to the changes seen in
IDL. The percent TG content in LDL was inversely correlated with HL
activity in women (r=-.48, P<.001), but this
association in men was less strong (r=-.29,
P<.05) (Fig 3). A comparison of the
regression slopes provided further support of the male-female
differences (LDL TG=6.0-0.04 HL in men versus LDL TG=8.0-0.1 HL in
women, P<.001).
|
Age, BMI, WHR, plasma TGs, fasting glucose, fasting insulin, LPL, and
HL all exhibited associations with LDL-I plasma concentration in
univariate analysis (Table 5). In
the multivariate model, age, sex, LPL, plasma TGs, and
fasting glucose were significant predictors, with the latter being the
most important. When all parameters in Table 5 were
included in a multiple regression analysis, they accounted for
26% of the variability in LDL-I. LDL-II exhibited significant
correlations with age, BMI, and plasma TGs, but none of these remained
significant on multivariate analysis. BMI, WHR,
plasma TGs, and HL exhibited the strongest relationships with LDL-III
in univariate analysis. Other factors of
significance included age, fasting glucose, fasting insulin, and LPL.
In the multivariate model GLM (A), sex and plasma TGs
were the only significant independent predictors. When these and the
other parameters in Table 5 were included in multiple
regression analysis, 42% of LDL-III variability was accounted
for. When sex was left out of the model (GLM [B]), HL and plasma TGs
were significant predictors of LDL-III; this reduced group of
parameters still explained 39% of the variability in this
subfraction. In an alternative approach to estimating the effect of
plasma TGs and HL on LDL-III levels, the sexes were divided, and
separate multiple regression analyses were performed with just
these two variables. In men plasma TGs alone explained 40% of
LDL-III variability (P<.0001), and HL was not a significant
predictor. In contrast, in women both plasma TGs and HL were
significant predictors (P=.002 and P<.0001,
respectively) that together explained 37% of LDL-III variation. The
sex difference was further examined by relating HL activity to LDL-III
concentrations adjusted for plasma TG level; HL activity was an
important correlate in women but not in men (r=.38,
P<.001 and r=.05, NS, respectively).
|
Plasma TG level was, therefore, the most important determinant of the
LDL subfraction profile in both univariate and
multivariate analysis. When the changes in
individual LDL subfraction distributions across the plasma TG range
were examined for the whole subject group, LDL-I exhibited a decrease
from mean concentration values of 100 mg/dL at a plasma TG level of 0.5
mmol/L to 40 mg/dL at a plasma TG level or 2.3 mmol/L (data not shown).
LDL-II showed a positive relationship (r=.47,
P<.001) at TG levels below 1.3 mmol/L and a negative
relationship (r=-.23, P<.001) above this
value.12 However, a gender difference was noted in these
associations. Specifically, the LDL-II concentration in women showed no
relationship (r=-.1, NS) with plasma TGs <1.3 mmol/L, but
a significant negative correlation was demonstrated in men
(r=-.45, P<.001) (Fig 4). The
concentration of LDL-III was generally low, with a mean of 30 mg/dL in
the range of plasma TG levels from 0.5 to 1.3 mmol/L. Above the latter
value there was a dramatic rise in LDL-III concentration in men but a
smaller increase in women (Fig 4). Linear regression analysis
in subjects with plasma TGs >1.3 mmol/L generated equations for
LDL-III concentration versus plasma TGs of LDL-III=119 TG-66.6,
r=.63, in men and LDL-III=47.4 TG-11.0, r=.49,
in women; the slopes of these lines differed significantly
(P<.001).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Age was not an entry criterion for this study, but due to the nature of the recruitment process the majority of participants were young to middle-aged adults. Only a few men and postmenopausal women were over the age of 55 years. The two sexes were well matched for age and exhibited the expected differences in body habitus. It was notable that while BMI was virtually identical in both groups, WHR was higher in the men, ie, they had increased central obesity. Plasma lipids were comparable, with the lower LDL-C level in women being balanced by the higher HDL level. HL activity showed a marked sex difference, whereas LPL activity did not. A number of questions were asked of the data. First, as total plasma cholesterol and TG levels varied across the range of values seen in the subjects, how did the VLDL1, VLDL2, IDL, and LDL concentrations alter? Second, what interrelationships existed between lipases and VLDL and LDL subfractions? Third, to what extent were changes in lipoprotein levels related to insulin resistance as revealed by the presence of central obesity and/or raised fasting insulin and glucose concentrations? Fourth, did the above associations depend on gender?
Increasing plasma cholesterol from the lower to upper quintiles of the distribution (3.5 to 7.0 mmol/L) was associated with a twofold rise in plasma LDL concentration and a similar increment in IDL. No relation was seen with VLDL1 and VLDL2 concentrations. The rise in LDL from low normal to high normal was not accompanied by any perturbation in the composition of the particle, either in the core-to-coat or cholesterol-to-protein ratios. That is, the increase was attributable to greater number of particles in the circulation. In contrast, we found that IDL exhibited distinct compositional variation across the normal plasma cholesterol range. As plasma cholesterol rose, so did the cholesteryl ester–TG ratio, indicating a change in the makeup of the particle core. Either IDL particles as a whole were being increasingly modified by lipid exchange (as described for LDL and HDL2 3 27 ) as their concentration increased in the circulation (possibly because of their longer residence time), or IDL is heterogeneous and composed of two subfractions, one of which is TG rich and the other cholesterol rich.8 If the latter situation is the case, it can be postulated that at higher plasma cholesterol levels there is a selective accumulation of the cholesterol-enriched IDL particles.
As plasma TG levels rose across the range seen in this cross-sectional survey, the plasma concentration of VLDL1 increased more rapidly than that of VLDL2. Closer examination of the scattergrams suggested that while VLDL1 and VLDL2 both increased at the same rate over the plasma TG range (0.5 to 1.0 mmol/L), above this value VLDL1 continued to rise, but VLDL2 showed a smaller increment. Kinetic studies28 of VLDL TG turnover have revealed that it is the synthesis and secretion of the lipid rather than its clearance rate that controls plasma levels in normal subjects. Thus, we interpret our observations to indicate that in subjects with high-normal plasma TG levels the liver, in response to an increased abundance of intracellular TGs, releases larger VLDL1 in preference to smaller VLDL2. This allows the transport of more lipid per lipoprotein particle. The total LDL concentration in this and an earlier study12 exhibited a relationship with plasma TGs that appeared biphasic in that a positive correlation was seen at lower plasma TG levels, but above 1.3 mmol/L the association was lost, suggesting that a plateau value had been reached. These relationships between plasma TGs and VLDL1, VLDL2, and LDL concentrations were present in both men and women, and we could not detect any significant gender-based differences in the correlation coefficients. What did differ between the sexes, however, was the LDL subfraction distribution as a function of plasma TG concentration.
LDL-I concentration was influenced by a number of factors including age, features of insulin resistance (increased fasting insulin and glucose), increased obesity, plasma TGs, and HL and LPL activities. In multivariate analysis fasting glucose was the most important predictor followed by age, plasma TGs, LPL, and WHR. The metabolic mechanisms underlying these associations are not yet clear. It is possible that the negative association with plasma TGs is due to cholesteryl ester transfer protein–mediated transfer of TGs from VLDL to the larger LDL species, which would improve their potential as a substrate for HL, similar to the situation for large HDL.2 3 27 The enzyme then lipolyzes the particle to denser particles (LDL-II or LDL-III). LPL activity, on the other hand, demonstrated a positive association with LDL-I, possibly because when LPL activity is high, the circulating levels of large TG-rich lipoproteins (including chylomicrons, which were not represented in the fasting TG measurement) are kept low,2 3 27 thus limiting TG exchange into LDL-I. Alternatively, high LPL activity may favor the rapid conversion of smaller VLDL particles to LDL-I. The effect of factors associated with insulin resistance, ie, higher plasma glucose levels and WHR, which was present in both sexes is, as yet, inexplicable.
LDL-II in both men and women exhibited a positive association with plasma TG level when the latter was <1.3 mmol/L12 (this value is the zenith of the quadratic regression line used to fit LDL-II to plasma TGs in men). At higher plasma TG levels (1.3 to 3.0 mmol/L) in men, there was a decrease in LDL-II12 (with a significant negative correlation), and LDL-III, which had been low when plasma TGs were <1.3 mmol/L, rose steeply. These data led us to postulate that the formation of LDL-III, possibly by remodeling of LDL-II, is increasingly favored in men as the plasma TG level rises above the 1.3 mmol/L threshold. In women the picture was different. At TG >1.3 mmol/L LDL-II did not fall, and little LDL-III was formed. Only 17% of women with plasma TGs above the threshold had an LDL-III >100 mg lipoprotein/dL plasma (the level at which significant CHD risk occurs12 ) compared with 42% in men.
The sex difference and the findings in Table 5 indicate that HL may
play an important role in determining the relative concentrations of
LDL-II and LDL-III in plasma. HL activity is twice as high in men as
women, and when LDL-III in the whole group was adjusted for variation
in plasma TGs, HL activity emerged as the strongest predictor of
LDL-III concentration. Generally, a combination of plasma TG >1.3
mmol/L and HL >15 U/L was required to generate LDL-III above the risk
level of 100 mg lipoprotein/dL plasma, at least in the subjects we
examined. Further support for the pivotal role of HL activity in
influencing LDL structure can be gained from examining the composition
of total LDL. In agreement with the earlier observation of Karpe et
al29 on the TG content of "light LDL"
(d=1.019 to 1.040 kg/L), percent LDL TG showed a significant
inverse correlation with HL activity that was stronger in women than in
men, indicating that in women HL activity was important in determining
the TG content of LDL; women with low HL had relatively TG-enriched
LDL. HL is also known to strongly influence HDL-C and
HDL2 levels,27 with high HL activity
associated with a low HDL2 concentration. These
putative HL-driven changes in LDL and HDL subfraction distributions go
a long way to explaining the differences in CHD risk between the sexes,
with women having less "atherogenic" LDL-III11 12
and more "cardioprotective"
HDL2.27 It is likely that the same
mechanism that causes the generation of smaller, denser particles
within HDL27 operates in the LDL density range. That is,
the lipoprotein is first made susceptible to the action of HL by
cholesteryl ester transfer protein–mediated TG transfer; we
postulate that it is the VLDL1 concentration that
determines the rate of TG transfer into LDL since large TG-rich VLDL is
a preferred substrate for cholesteryl ester transfer protein
action.30 HL then acts on LDL-II to hydrolyze the
TG-enriched core and generate LDL-III. On the other hand, if the enzyme
activity is low, then LDL-II remains the major species in plasma and is
relatively TG enriched (as suggested by the data in Fig 3). HL is
regulated by sex steroid hormones, and so this final step is possibly a
function of androgen/estrogen status between and within the sexes. The
present findings amplify and set in context the earlier reports of
Zambon et al,31 Jansen et al,32 and Watson et
al21 on the role of HL in determining LDL subfraction
distribution. The importance of HL becomes clear only when the subject
groups exhibit a wide range for its activity, eg, when both sexes are
examined.21 The previous data of Zambon et al and Jansen
et al were collected in men. Our findings agree with the latter study,
in which no overall independent influence of HL on LDL subfraction
pattern was reported, whereas in the former report a sufficient number
of subjects with a low HL were included to see the effect.
The syndrome of insulin resistance has been linked to the appearance of raised plasma TGs, lower HDL-C, and the presence of small LDL in gel electrophoresis patterns.13 In the present study we found that features of insulin resistance (increased WHR and raised fasting insulin or glucose) were correlated with LDL subfraction concentrations, particularly LDL-I (negatively) and LDL-III (positively). On the basis of the argument outlined above, it can be hypothesized that in subjects with insulin resistance the change in the LDL subfraction profile is due mainly to an elevation in plasma TG levels above the 1.3-mmol/L threshold. It is predictable that VLDL1 is specifically increased in the disorder since normally insulin acts to inhibit hepatic TG release in the form of large VLDL,15 and subjects with non–insulin-dependent diabetes mellitus have a preponderance of large, TG-rich VLDL.15 33 Furthermore, we suggest that in many subjects the generation of small, dense LDL may be the result of two hormonal effects: first, the failure of insulin action, which leads to higher VLDL1 levels, and as a consequence of this, increased neutral lipid exchange with LDL-II; second, high androgen activity, which stimulates HL activity and the conversion of TG-enriched LDL-II to LDL-III. It is noteworthy that WHR correlated with HL activity, and that insulin resistance itself and the presence of central obesity can lead to changes in androgen/estrogen balance.34
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This work was supported in part by grant No. 190/1242 from the British Heart Foundation. Dr Tan is the recipient of a Health Manpower Development Plan scholarship from the Ministry of Health of Singapore. Dr Watson was supported by a fellowship from the Wellcome Trust. The technical assistance of Grace Lindsay, Moira Devine, Philip Stewart, and Elizabeth Murray is gratefully acknowledged. Nancy Thomson provided excellent secretarial help in the preparation of this manuscript.
Received February 27, 1995; accepted August 21, 1995.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Austin MA, King M-C, Vranigan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
2. Packard CJ, Shepherd J. Metabolic basis of the link between plasma triglycerides and coronary heart disease. In: Born GVR, Schwartz CJ, eds. New Horizons in Coronary Heart Disease. London, England: Current Science; 1993:5.1-5.11.
3.
Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg
S. Plasma triglyceride determines
structure-composition in low- and high-density
lipoproteins. Arteriosclerosis.. 1984;4:225-231.
4.
Patsch W, Patsch JR, Kostner GM, Saller S,
Braunsteiner H. Isolation of subfractions of human very low
density lipoproteins by zonal
ultracentrifugation. J Biol
Chem.. 1978;253:4911-4915.
5. Kuchinskiene Z, Carlson LA. Composition, concentration and size of low density lipoproteins and of subfractions of very low density lipoproteins from serum of normal men and women. J Lipid Res.. 1982;23:762-769. [Abstract]
6. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res.. 1982;23:97-104. [Abstract]
7. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein subfractions from plasma by density gradient ultracentrifugation. Arteriosclerosis.. 1990;83:59-67.
8.
Musliner TA, Giotas C, Krauss RM. Presence of
multiple subpopulations of lipoproteins of intermediate density in
normal subjects.
Arteriosclerosis.. 1986;6:79-87.
9. Packard CJ, Munro A, Lorimer AR, Gotto AM, Shepherd J. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest.. 1984;74:2178-2192.
10. Demant T, Shepherd J, Packard CJ. Very low density lipoprotein apolipoprotein B metabolism in humans. Wien Klin Wochenschr.. 1988;66:703-712.
11.
Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett
WC, Krauss RM. Low density lipoprotein subclass patterns and
risk of myocardial infarction. JAMA.. 1988;260:1917-1921.
12. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease. Atherosclerosis.. 1994;106:241-253. [Medline] [Order article via Infotrieve]
13. Reaven GM, Chen YDI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinaemia in individuals with small dense low density lipoprotein particles. J Clin Invest.. 1993;92:141-146.
14. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes.. 1988;37:1595-1607. [Abstract]
15. Taskinen M-R, Packard CJ, Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes.. 1990;39:1017-1027. [Abstract]
16.
Selby JV, Austin MA, Newman B, Zhang D, Quesenberry CP,
Mayer EJ, Krauss RM. LDL subclass phenotypes and the
insulin-resistance syndrome in women.
Circulation. 1993;88:381-387.
17. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-505.
18. Ashwell M, Chinn S, Stalley S, Garrow JS. Female fat distribution: a simple classification based on two circumference measurements. Int J Obes.. 1982;6:289-302.
19. Lipid Research Clinics Program. Manual of Laboratory Operations, I: Lipid and Lipoprotein Analysis. Bethesda, Md: National Institutes of Health; 1975:75. US Dept of Health, Education, and Welfare publication NIH 75-628.
20. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitation analysis of serum lipoproteins. In: Nelson GJ, ed. Blood Lipid and Lipoproteins: Quantitation, Composition and Metabolism. New York, NY: Wiley-Interscience; 1972:181-274.
21.
Watson TDG, Caslake MJ, Freeman DJ, Griffin BA, Hinnie
J, Packard CJ, Shepherd J. Determinants of low-density
lipoprotein subfraction distribution and concentrations in young
normolipidemic subjects.
Arteriosclerosis.. 1994;14:902-910.
22. Schumaker VN, Phillips ML, Chatterton JE. Apolipoprotein B and low-density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins. Adv Protein Chem.. 1994;45:205-248. [Medline] [Order article via Infotrieve]
23. Watson TDG, Burns L, Packard CJ, Shepherd J. Selective determination of lipoprotein lipase and hepatic triglyceride lipase in heparinised plasma from horses. Am J Vet Res.. 1992;54:771-775.
24.
Barrett-Connor E, Bush TL. Estrogen and
coronary heart disease in women. JAMA.. 1991;265:1861-1867.
25. Campos H, Wilson PWF, Jimemez D, McNamara JR, Ordovas J, Schaefer EJ. Differences in apolipoproteins and low density lipoprotein subfractions in postmenopausal women on and off estrogen therapy: results from the Framingham Offspring Study. Metabolism.. 1990;39:1033-1038. [Medline] [Order article via Infotrieve]
26.
Applebaum-Bowden D, McLean P, Steinmetz A, Fontana D,
Matthys C, Warwick GR, Cheung M, Albers JJ, Hazzard WR.
Lipoprotein, apolipoprotein and lipolytic enzyme changes
following estrogen administration in postmenopausal women.
J Clin Endocrinol Metab.. 1988;67:30-35.
27. Patsch JR, Prasad S, Gotto AM, Patsch W. High density lipoprotein2: relationship of the plasma levels of this lipoprotein species to its composition to the magnitude of postprandial lipemia and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest.. 1987;80:341-347.
28.
Stalenhoef AFH, Demacker PNM, Lutterman JA, Laar AV.
Plasma lipoproteins, apolipoproteins and
triglyceride metabolism in familial
hypertriglyceridemia.
Arteriosclerosis.. 1986;6:387-394.
29. Karpe F, Tornvall P, Olivecrona T, Steiner G, Carlson LA, Hamsten A. Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis.. 1993;98:33-49.[Medline] [Order article via Infotrieve]
30. Eisenberg S. Preferential enrichment of large-sized very low density lipoprotein populations with transferred cholesteryl esters. J Lipid Res.. 1985;26:487-493. [Abstract]
31.
Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell
JD. Effect of hepatic lipase on LDL in normal men and those with
coronary artery disease. Arterioscler
Thromb.. 1993;13:147-153.
32. Jansen H, Hop W, van Tol A, Bruschke AVG, Birkenhager JC. Hepatic lipase and lipoprotein lipase are not major determinants of low density lipoprotein subclass pattern in human subjects with coronary heart disease. Atherosclerosis.. 1994;107:45-54.[Medline] [Order article via Infotrieve]
33. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res.. 1987;28:613-628. [Medline] [Order article via Infotrieve]
34. Kissebah AH, Peiris AN. Biology of regional fat distribution: relationship to non-insulin dependent diabetes mellitus. Diabetes Metab Rev.. 1989;5:83-109.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  D. B. van Schalkwijk, A. A. de Graaf, B. van Ommen, K. van Bochove, P. C. N. Rensen, L. M. Havekes, N. C. A. van de Pas, H. C. J. Hoefsloot, J. van der Greef, and A. P. Freidig Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size J. Lipid Res., December 1, 2009; 50(12): 2398 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Catalano, E. Duchene, Z. Julia, W. Le Goff, E. Bruckert, M. J. Chapman, and M. Guerin Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects J. Lipid Res., March 1, 2008; 49(3): 635 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Adiels, J. Boren, M. J. Caslake, P. Stewart, A. Soro, J. Westerbacka, B. Wennberg, S.-O. Olofsson, C. Packard, and M.-R. Taskinen Overproduction of VLDL1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1697 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Freedman, J. D. Otvos, E. J. Jeyarajah, I. Shalaurova, L. A. Cupples, H. Parise, R. B. D'Agostino, P. W.F. Wilson, and E. J. Schaefer Sex and Age Differences in Lipoprotein Subclasses Measured by Nuclear Magnetic Resonance Spectroscopy: The Framingham Study Clin. Chem., July 1, 2004; 50(7): 1189 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Krauss Lipids and Lipoproteins in Patients With Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1496 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Deeb, A. Zambon, M. C. Carr, A. F. Ayyobi, and J. D. Brunzell Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet J. Lipid Res., July 1, 2003; 44(7): 1279 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Berneis and R. M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J. Lipid Res., September 1, 2002; 43(9): 1363 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S Freedman, B. A Bowman, J. D Otvos, S. R Srinivasan, and G. S Berenson Differences in the relation of obesity to serum triacylglycerol and VLDL subclass concentrations between black and white children: the Bogalusa Heart Study Am. J. Clinical Nutrition, May 1, 2002; 75(5): 827 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Pirwany, N. Sattar, I. A. Greer, C. J. Packard, and R. Fleming Supraphysiological concentrations of estradiol in menopausal women given repeated implant therapy do not adversely affect lipid profiles Hum. Reprod., March 1, 2002; 17(3): 825 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Carr, J. E. Hokanson, A. Zambon, S. S. Deeb, P. H. R. Barrett, J. Q. Purnell, and J. D. Brunzell The Contribution of Intraabdominal Fat to Gender Differences in Hepatic Lipase Activity and Low/High Density Lipoprotein Heterogeneity J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2831 - 2837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Marz, H. Scharnagl, C. Abletshauser, M. M. Hoffmann, A. Berg, J. Keul, H. Wieland, and M. W. Baumstark Fluvastatin Lowers Atherogenic Dense Low-Density Lipoproteins in Postmenopausal Women With the Atherogenic Lipoprotein Phenotype Circulation, April 17, 2001; 103(15): 1942 - 1948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. H. Juo, Z. Han, J. D. Smith, L. Colangelo, and K. Liu romoter polymorphisms of hepatic lipase gene influence HDL2 but not HDL3 in African American men: CARDIA study J. Lipid Res., February 1, 2001; 42(2): 258 - 264. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. J. DEIGHAN, M. J. CASLAKE, M. MCCONNELL, J. M. BOULTON-JONES, and C. J. PACKARD Comparative Effects of Cerivastatin and Fenofibrate on the Atherogenic Lipoprotein Phenotype in Proteinuric Renal Disease J. Am. Soc. Nephrol., February 1, 2001; 12(2): 341 - 348. [Abstract] [Full Text]
|
|
|
|
|
|
K. Winkler, B. Wetzka, M. M. Hoffmann, I. Friedrich, M. Kinner, M. W. Baumstark, H. Wieland, W. März, and H. P. Zahradnik Low Density Lipoprotein (LDL) Subfractions during Pregnancy: Accumulation of Buoyant LDL with Advancing Gestation J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4543 - 4550. [Abstract] [Full Text]
|
|
|
|
|
|
A. A. Rivellese, L. Patti, G. Romano, F. Innelli, L. Di Marino, G. Annuzzi, M. Iavicoli, G. A. Coronel, and G. Riccardi Effect of Insulin and Sulfonylurea Therapy, at the Same Level of Blood Glucose Control, on Low Density Lipoprotein Subfractions in Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4188 - 4192. [Abstract] [Full Text]
|
|
|
|
|
|
R. J Havel Genetic underpinnings of LDL size and density: a role for hepatic lipase? Am. J. Clinical Nutrition, June 1, 2000; 71(6): 1390 - 1391. [Full Text] [PDF]
|
|
|
|
|
|
P. Couture, J. D. Otvos, L. A. Cupples, C. Lahoz, P. W. F. Wilson, E. J. Schaefer, and J. M. Ordovas Association of the C-514T Polymorphism in the Hepatic Lipase Gene With Variations in Lipoprotein Subclass Profiles : The Framingham Offspring Study Arterioscler Thromb Vasc Biol, March 1, 2000; 20(3): 815 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Packard, T. Demant, J. P. Stewart, D. Bedford, M. J. Caslake, G. Schwertfeger, A. Bedynek, J. Shepherd, and D. Seidel Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions J. Lipid Res., February 1, 2000; 41(2): 305 - 318. [Abstract] [Full Text]
|
|
|
|
|
|
S. Bioletto, A. Golay, R. Munger, B. Kalix, and R. W James Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects1 Am. J. Clinical Nutrition, February 1, 2000; 71(2): 443 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Skoglund-Andersson, R. Tang, M. G. Bond, U. de Faire, A. Hamsten, and F. Karpe LDL Particle Size Distribution Is Associated With Carotid Intima-Media Thickness in Healthy 50-Year-Old Men Arterioscler Thromb Vasc Biol, October 1, 1999; 19(10): 2422 - 2430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zambon, J. E. Hokanson, B. G. Brown, and J. D. Brunzell Evidence for a New Pathophysiological Mechanism for Coronary Artery Disease Regression : Hepatic Lipase–Mediated Changes in LDL Density Circulation, April 20, 1999; 99(15): 1959 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Rainwater, L. Almasy, J. Blangero, S. A. Cole, J. L. VandeBerg, J. W. MacCluer, and J. E. Hixson A Genome Search Identifies Major Quantitative Trait Loci on Human Chromosomes 3 and 4 That Influence Cholesterol Concentrations in Small LDL Particles Arterioscler Thromb Vasc Biol, March 1, 1999; 19(3): 777 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zambon, S. S. Deeb, J. E. Hokanson, B. G. Brown, and J. D. Brunzell Common Variants in the Promoter of the Hepatic Lipase Gene Are Associated With Lower Levels of Hepatic Lipase Activity, Buoyant LDL, and Higher HDL2 Cholesterol Arterioscler Thromb Vasc Biol, November 1, 1998; 18(11): 1723 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Hubel, Y. Shakir, M. J. Gallaher, M. K. McLaughlin, and J. M. Roberts Low-Density Lipoprotein Particle Size Decreases During Normal Pregnancy in Association With Triglyceride Increases Reproductive Sciences, September 1, 1998; 5(5): 244 - 250. [Abstract] [PDF]
|
|
|
|
|
|
C. J. Packard and J. Shepherd Lipoprotein Heterogeneity and Apolipoprotein B Metabolism Arterioscler Thromb Vasc Biol, December 1, 1997; 17(12): 3542 - 3556. [Abstract] [Full Text]
|
|
|
|
|
|
V. Anber, J. S. Millar, M. McConnell, J. Shepherd, and C. J. Packard Interaction of Very-Low-Density, Intermediate-Density, and Low-Density Lipoproteins With Human Arterial Wall Proteoglycans Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2507 - 2514. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Sattar, C. J Packard, and A. J Jaap Metabolic effects of hormone replacement preparations BMJ, June 22, 1996; 312(7046): 1608 - 1608. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||